Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.